Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: Systematic review and meta-analysis

Circulation: Heart Failure

Volumn 5, Issue 5, 2012, Pages 552-559

  Schinkel, Arend F L ^a   Vriesendorp, Pieter A ^a   Sijbrands, Eric J G ^a   Jordaens, Luc J L M ^a   Ten Cate, Folkert J ^a   Michels, Michelle ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Complications; Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Prognosis; Sudden cardiac death

Indexed keywords

ADULT; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; COMPLICATION; DEVICE INFECTION; FAINTNESS; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE WALL; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEAD DISPLACEMENT; LEAD MALFUNCTION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PSYCHOLOGICAL COMPLICATION; REVIEW; RISK FACTOR; SUDDEN DEATH; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868656402     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.969626     Document Type: Review

References (34)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308-1320. (Pubitemid 34250486)
2. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349:1064-1075. (Pubitemid 37098275)
3. Kim JH, Malhotra R, Chiampas G, d'Hemecourt P, Troyanos C, Cianca J, Smith RN, Wang TJ, Roberts WO, Thompson PD, Baggish AL; Race Associated Cardiac Arrest Event Registry (RACER) Study Group. Cardiac arrest during long-distance running races. N Engl J Med. 2012;366:130-140.
4. Primo J, Geelen P, Brugada J, Filho AL, Mont L, Wellens F, Valentino M, Brugada P. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 1998;31:1081-1085.
5. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596-1601.
6. Kaski JP, Tomé Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, McKenna WJ, Elliott PM. Outcomes after implantable cardioverter- defibrillator treatment in children with hypertrophic cardiomyopathy. Heart. 2007;93:372-374. (Pubitemid 46579536)
7. O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tso-volas K, Al-Shaikh S, Rahman SM, Arnous S, Jones S, McKenna W, Elliott P. The long-term survival and the risks and Benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116-125.
8. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, Bardy GH, Favale S, Rea RF, Boriani G, Estes NA 3rd, Spirito P. Eff-cacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373. (Pubitemid 30084534)
9. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA 3rd, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298:405-412. (Pubitemid 47124061)
10. Maron BJ, Semsarian C, Shen WK, Link MS, Epstein AE, Estes NA 3rd, Almquist A, Giudici MC, Haas TS, Hodges JS, Spirito P. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic car-diomyopathy. Heart Rhythm. 2009;6:599-602.
11. Sherrid MV, Cotiga D, Hart D, Ehlert F, Haas TS, Shen WK, Link MS, Estes NA 3rd, Epstein AE, Semsarian C, Daubert JP, Winters SL, Giu-dici MC, Maron BJ. Relation of 12-lead electrocardiogram patterns to implanted defibrillator- terminated ventricular tachyarrhythmias in hy-pertrophic cardiomyopathy. Am J Cardiol. 2009;104:1722-1726.
12. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic car-diomyopathy. Pacing Clin Electrophysiol. 2003;26:1887-1896. (Pubitemid 37130061)
13. Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, Semsarian C. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol. 2004;93:1192-1194. (Pubitemid 38521061)
14. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardio-myopathy. Heart Rhythm. 2005;2:814-819. (Pubitemid 41038399)
15. Maron BJ, Haas TS, Shannon KM, Almquist AK, Hodges JS. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm. 2009;6:993-997.
16. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005;28:295-300. (Pubitemid 40604043)
17. Przybylski A, Malecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, Ruzyllo W, Szwed H. Implantable cardioverter- defibrillators in patients with hypertrophic cardiomyopathy - dilemmas and difficulties. Kardiol Pol. 2005;63:391-7; discussion 398. (Pubitemid 41624884)
18. Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczynska-Mazuruk R, Ruzyllo W, Szwed H. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21:883-889.
19. Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers]. Rev Esp Cardiol. 2006;59:537-544. (Pubitemid 44203197)
20. Medeiros Pde T, Martinelli Filho M, Arteaga E, Costa R, Siqueira S, Mady C, Piegas LS, Ramires JA. Hypertrophic cardiomyopathy: the importance of arrhythmic events in patients at risk for sudden cardiac death. Arq Bras Cardiol. 2006;87:649-657.
21. Cha YM, Gersh BJ, Maron BJ, Boriani G, Spirito P, Hodge DO, Weivoda PL, Trusty JM, Friedman PA, Hammill SC, Rea RF, Shen WK. Elec-trophysiologic manifestations of ventricular tachyarrhythmias provoking appropriate defibrillator interventions in high-risk patients with hypertro-phic cardiomyopathy. J Cardiovasc Electrophysiol. 2007;18:483-487. (Pubitemid 46650337)
22. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, Schaff HV, Tajik AJ, Gersh BJ. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrilla-tor discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28:2583-2588. (Pubitemid 350071505)
23. Kiernan TJ, Weivoda PL, Somers VK, Ommen SR, Gersh BJ. Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2008;31:1253-1258.
24. Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA. Device complications and inappropriate implantable cardio-verter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart. 2009;95:709-714.
25. Woo A, Monakier D, Harris L, Hill A, Shah P, Wigle ED, Rakowski H, Rozenblyum E, Cameron DA. Determinants of implantable defibrilla-tor discharges in high-risk patients with hypertrophic cardiomyopathy. Heart. 2007;93:1044-1045. (Pubitemid 47310979)
26. Cuoco FA, Spencer WH 3rd, Fernandes VL, Nielsen CD, Nagueh S, Stur-divant JL, Leman RB, Wharton JM, Gold MR. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52:1718-1723.
27. Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, Connelly DT, Griffith MJ, McKeown PP, McLeod K, Morgan JM, Sadoul N, Chojnowska L, Huang CL, Grace AA. Paced ventricular elec-trogram fractionation predicts sudden cardiac death in hypertrophic car-diomyopathy. Eur Heart J. 2008;29:1653-1661. (Pubitemid 351957538)
28. Hauser RG, Katsiyiannis WT, Gornick CC, Almquist AK, Kallinen LM. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. Europace. 2010;12:395-401.
29. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, Gersh BJ, Ommen SR. Role of family history of sudden death in risk strat-ification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481-1486.
30. Prinz C, Vogt J, Bitter T, Muntean BG, Hering D, Horstkotte D, Faber L. Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death. Acta Cardiol. 2010;65:521-525.
31. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.
32. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; American Society of Echo-cardiography; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertro-phic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783-e831.
33. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, Simon AW. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2493-2497. (Pubitemid 43866387)
34. Peterson PN, Daugherty SL, Wang Y, Vidaillet HJ, Heidenreich PA, Curtis JP, Masoudi FA; National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation. 2009;119:1078-1084.